Mendeleev Commun., 2011, 21, 94–96
Table 2 Synthesis of 4-aminofuran-2(5H)-one derivatives 4 from compounds 1 and 2 in [bmim][BF4].
Entry
Product
R1
R2
R3
R4
T/°C (lit.)
t/h (lit.)
Yield (%) (lit.)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
4a
4b
4c
4d
4e
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)4–
–(CH2)4–
–(CH2)4–
–(CH2)5–
–(CH2)6–
20 (20a)
1 (48a)
1 (140a, 4b)
1 (48a)
1 (140a)
4 (48a, 7c)
2 (250a)
8 (6c)
6 (140a)
2 (12c)
80 (73a)
85 (67a, 62b)
88 (53a)
85 (72a)
90 (59a, 47c)
87 (82a)
86 (62c)
80 (71a)
20 (20a, 100b)
30 (20a)
–(CH2)2O(CH2)2–
–(CH2)2N(Me)(CH2)2–
–CH(Me)(CH2)4–
–(CH2)2N[C(O)Ph](CH2)2–
–(CH2)2N(CO2Et)(CH2)2–
2 = imidazole
2 = (S)-anabasine
2 = (S)-cytisine
–(CH2)5–
–(CH2)2N(Me)(CH2)2–
–(CH2)4–
20 (20a)
40 (20a, 65c)
20 (20a)
4f
4g
4h
4i
20 (65c)
20 (20a)
60 (65c)
18 + 52d (35 + 8c,d
99 (62c, 74e)
70 (64g)
)
4j
20 (65c, 100e)
20 (20g)
6 (20c, 12e)
8 (150g)
1 (48h)
4kf
4lf
4mf
4nf
4of
4pf
4q
4r
20 (20h)
95 (65h)
20 (20h)
1 (45h)
96 (60h)
Me
Me
Me
Et
20 (20h)
1 (48h)
88 (66h)
–(CH2)4–
Me2CH(CH2)2
20 (20h)
1 (48h)
90 (68h)
–(CH2)5–
–(CH2)5–
–(CH2)5–
–(CH2)5–
Me2CH(CH2)2
Bn
Bn
CH(Me)Ph
20 (20g)
5 (25g)
88 (60g)
Bn
H
H
20 (20a)
4 (250a)
3 (24c, 8e)
8 (12a)
82 (78a)
20 (20c, 100e)
20 (20a)
80 (70c, 67e)
70 (58a)
4s
aSolvent – Et2O, data according to ref. 7(a). bNeat conditions, data according to ref. 7(a). cSolvent – MeOH, data according to ref.7(a). dYield of compound 3i.
eSolvent – BuOH, data according to ref. 7(b). fNew compounds. gSolvent – Et2O/MeOH (2:1, v/v). hSolvent – Et2O.
fragments acted as Michael acceptors. Cyclic amines (entries
1–15), in particular alkaloids (entries 10, 11), as well as acyclic
secondary (entries 16, 17) or primary (entries 18, 19) amines
were used as nucleophiles.
organic solvents as well and became convinced that the IL medium
gave much better results in terms of both the product yield and
the reaction rate (Table 2). Positive IL impact may be attributed
to ion–dipole interactions in the IL medium, which facilitate the
charge separation in compounds 1 and/or 3 and promote reactions
(Figure 1).
As a rule, yields of corresponding butenolides 4a–s were
close or higher than those reported in literature. Furthermore,
the reaction time was much shorter in the IL medium than that in
traditional organic solvents (TLC monitoring). The sole exception
was the reaction between alkyne 1a and imidazole (entry 9), in
which furan derivative 4i was formed in only 18% yield and the
major product was enamine 3i.‡ We succeeded in synthesizing
several new compounds in the IL medium, in particular (S)-cytisine-
derived butenolide 4k (entry 11) and compounds 4l–p (entries
12–16).§ For comparison, we synthesized these compounds in
2.6 (s, 1H, H7-cytisine), 3.15 (s, 1H, H9-cytisine), 3.30 (d, 2H, H10-cytisine,
J 12.5 Hz), 3.65–3.95 (m, 3H, NCH2), 4.20 (d, 1H, NCH2, J 12.5 Hz), 4.60
(s, 1H, =CH), 6.07 (d, 1H, H5-cytisine, J 10.4 Hz), 6.46 (d, 1H, H3-cytisine,
J 12.5 Hz), 7.31 (t, 1H, H4-cytisine, J 10.4 Hz). Found (%): C, 70.81;
H, 7.17; N, 8.09. Calc. for C20H24N2O3 (%): C, 70.56; H, 7.11; N, 8.23.
ChiralcelAD-H, eluent hexane–PriOH (1:1), 0.8 ml min–1, 220 nm, reten-
tion time 8.5 min (single); eluent hexane–PriOH (7:3), 0.8 ml min–1, 220 nm,
retention time 16.1 min (single).
4-Piperidino-1-oxaspiro[4.4]non-3-en-2-one 4l: white solid, 0.25 g (95%),
‡
Synthesis of compounds 3i and 4i. A mixture of alkyne 1a (0.18 g,
1
mp 110–111°C. IR (KBr, n/cm–1): 1722 (C=O), 1596 (C=C). H NMR
1.0 mmol), imidazole (0.12 g, 1.5 mmol) and [bmim][BF4] (0.69 g, 3.0 mmol)
was stirred at 60°C for 2 h, cooled to ambient temperature and successively
extracted with light petroleum (5 ml), light petroleum–diethyl ether (1:10)
(5 ml) and light petroleum–benzene (1:1) (5 ml). The combined extracts
were evaporated to a half volume, the precipitated solid was filtered off
and crystallized from the light petroleum–Et2O–EtOAc–CHCl3 (5:5:2:1)
mixture to afford methyl 3-(1-hydroxycyclohexyl)-3-(1H-imidazol-1-yl)-
acrylate 3i, yellowish solid, 0.13 g (52%), mp 110–111°C. IR (KBr,
n/cm–1): 1660, 1732, 3112. 1H NMR (300 MHz, DMSO-d6) d: 0.95–1.75
(m, 10H, CH2, cyclohexyl), 3.50 (s, 3H, OMe), 5.25 (s, 1H, OH), 6.35 (s,
1H, =CH), 6.90, 7.20, 7.45 (3s, 1H each, imidazole). Found (%): C, 62.61;
H, 7.13; N, 10.98. Calc. for C13H18N2O3 (%): C, 62.38; H, 7.25; N,11.19.
Evaporation of mother liquor afforded 4-(1H-imidazol-1-yl)-1-oxaspiro-
[4.5]dec-3-en-2-one 4i, white solid, 40 mg (18%), mp 180–181°C. IR (KBr,
n/cm–1): 1632, 1748, 3148. 1H NMR (300 MHz, DMSO-d6) d: 1.43–1.85
(m, 10H, CH2, cyclohexyl), 6.52 (s, 1H, =CH), 7.21, 7.89, 8.50 (3s, 1H each,
imidazole). Found (%): C, 66.27; H, 6.68; N, 12.57. Calc. for C12H14N2O2
(%): C, 66.04; H, 6.47; N, 12.84.
(300 MHz, CDCl3) d: 1.56–1.90 (m, 4H, CH2), 1.90–2.18 (m, 6H, CH2,
piperidine), 3.19–3.37 (m, 4H, NCH2, piperidine), 4.61 (s, 1H, =CH).
Found (%): C, 70.31; H, 8.79; N, 6.15. Calc. for C13H19NO2 (%): C, 70.55;
H, 8.65; N, 6.33.
4-(4-Methylpiperazin-1-yl)-1-oxaspiro[4.4]non-3-en-2-one 4m: white
solid, 0.23 g (96%), mp 109–110°C. IR (KBr, n/cm–1): 1722 (C=O), 1588
1
(C=O). H NMR (300 MHz, CDCl3) d: 1.69–2.15 (m, 8H, CH2, cyclo-
pentyl), 2.42 (s, 3H, NMe), 2.48, 3.33 (2t, 4H each, NCH2, J 4.6 Hz),
4.63 (s, 1H, =CH). Found (%): C, 66.25; H, 8.61; N, 11.64. Calc. for
C13H20N2O2 (%): C, 66.07; H, 8.53; N, 11.86.
5,5-Dimethyl-4-pyrrolidinofuran-2(5H)-one 4n: yellowish solid, 0.16 g
(88%), mp 105–106°C. IR (KBr, n/cm–1): 1722 (C=O), 1588 (C=C). 1H NMR
(300 MHz, CDCl3) d: 1.6 (s, 6H, Me), 1.92–2.09 (m, 4H, CH2, pyrro-
lidine), 3.38 (br.s, 4H, NCH2), 4.38 (s, 1H, =CH). Found (%): C, 65.92;
H, 8.39; N, 7.58. Calc. for C10H15NO2 (%): C, 66.27; H, 8.34; N, 7.73.
5-Methyl-5-ethyl-4-pyrrolidinofuran-2(5H)-one 4o: white solid, 0.17 g
(90%), mp 65–66°C. IR (KBr, n/cm–1): 1722 (C=O), 1588 (C=C). 1H NMR
(300 MHz, CDCl3) d: 0.8 (t, 3H, CH2Me, J 7.4 Hz), 1.51 (s, 3H, CMe),
1.83 (sept., 2H, CH2Me, J 7.4 Hz), 1.85–2.05 (m, 4H, CH2 cycl.), 3.36 (br.s,
4H, NCH2), 4.37 (s, 1H, =CH). Found (%): C, 67.89; H, 8.64; N, 6.95.
Calc. for C11H17NO2 (%): C, 67.66; H, 8.78; N, 7.17.
4-[Bis(4-methylbutyl)amino]-1-oxaspiro[4.5]dec-3-en-2-one 4p: white
solid, 0.24 g (88%), mp 92–93°C. IR (KBr, n/cm–1): 1720 (C=O), 1590
(C=C). 1H NMR (300 MHz, CDCl3) d: 0.95 (d, 12H, Me, J 6.4 Hz),
1.05–2.00 (m, 14H, CH2), 2.1 (sept., 2H, CH, J 6.5 Hz), 3.1 (d, 4H, NCH2,
J 7.6 Hz), 4.47 (s, 1H, =CH). Found (%): C, 73.88; H, 10.68; N, 4.89.
Calc. for C19H33NO2 (%): C, 74.22; H, 10.81; N, 4.56.
§
4-[(S)-2-(3-Pyridyl)piperidin-1-yl]-1-oxaspiro[4.5]dec-3-en-2-one
4j: white solid, 0.31 g (99%), mp 220.5–222°C (lit.,7(b) 221–222°C),
[a]D20 –169 (c 0.47, CHCl3), Chiralcel AD-H, eluent hexane–PriOH (1:1),
0.8 ml min–1, 254 nm, retention time 8.2 min (single); eluent hexane–
PriOH (7:3), 0.8 ml min–1, 254 nm, retention time 9.9 min (single).
(1R,5S)-3-(2-Oxo-1-oxaspiro[4.5]dec-3-en-4-yl)-1,2,3,4,5,6-hexa-
hydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one 4k: white solid,
0.24 g (70%), mp 285–287°C (decomp.), [a]D20 –413 (c 0.45, CHCl3).
IR (KBr, n/cm–1): 1740 (C=O), 1630 (C=C). 1H NMR (300 MHz, CDCl3)
d: 0.98–1.98 (m, 10H, CH2, cyclohexyl), 1.98–2.24 (m, 2H, H8-cytisine),
– 95 –